Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a common bone drug help HIV patients with brittle bones?

NCT ID NCT00120757

First seen Apr 09, 2026 · Last updated May 24, 2026 · Updated 6 times

Summary

This study tested whether alendronate, a drug used for osteoporosis, can improve bone density in people with HIV who also have weak bones. About 140 participants received either alendronate or a placebo for two years, along with calcium and vitamin D. The main goal was to measure changes in bone density in the spine and hip.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Hôpital Necker service des Maladies Infectieuses

    Paris, 75015, France

  • Service de Medecine Interne hopital Avicenne

    Bobigny, 93009 cedex, France

  • Service de Rhumatologie hopital Pitie-Salpetriere

    Paris, 75013, France

Conditions

Explore the condition pages connected to this study.